Zofia Piotrowska
About
Zofia Piotrowska is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Cancer Research.
According to data from OpenAlex, Zofia Piotrowska has authored 122 papers receiving a total of 2.6k indexed citations (citations by other indexed papers that have themselves been cited), including 108 papers in Pulmonary and Respiratory Medicine, 96 papers in Oncology and 21 papers in Cancer Research. Recurrent topics in Zofia Piotrowska's work include Lung Cancer Treatments and Mutations (108 papers), Colorectal Cancer Treatments and Studies (53 papers) and Lung Cancer Research Studies (33 papers). Zofia Piotrowska is often cited by papers focused on Lung Cancer Treatments and Mutations (108 papers), Colorectal Cancer Treatments and Studies (53 papers) and Lung Cancer Research Studies (33 papers). Zofia Piotrowska collaborates with scholars based in United States, Netherlands and Japan. Zofia Piotrowska's co-authors include Lecia V. Sequist, Jeffrey A. Engelman, Matthew J. Niederst, Elizabeth L. Lockerman, Hillary E. Mulvey, Haichuan Hu, Angel R. Garcia, Andrew J. Piper‐Vallillo, Alice T. Shaw and Justin F. Gainor and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Cancer.
In The Last Decade
Zofia Piotrowska
115 papers receiving 2.5k citations
Hit Papers
Peers
Zofia Piotrowska
Teresa Morán Spain
Alessandro Leonetti Italy
Francesco Facchinetti Italy
Jennifer Tursi Italy
Maximilian J. Hochmair Austria
C. Anger United Kingdom
Hai‐Yan Tu China
Miloš Pešek Czechia
Richard Eek Australia
Katsuhiro Masago Japan
Citations per year, relative to Zofia Piotrowska Zofia Piotrowska (= 1×)
peers
Teresa Morán
Countries citing papers authored by Zofia Piotrowska
Since
Specialization
Citations
This map shows the geographic impact of Zofia Piotrowska's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Zofia Piotrowska with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Zofia Piotrowska more than expected).
Fields of papers citing papers by Zofia Piotrowska
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Zofia Piotrowska. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Zofia Piotrowska. The network helps show where Zofia Piotrowska may publish in the future.
Co-authorship network of co-authors of Zofia Piotrowska
This figure shows the co-authorship network connecting the top 25 collaborators of Zofia Piotrowska. A scholar is included among the top collaborators of Zofia Piotrowska based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Zofia Piotrowska. Zofia Piotrowska is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Banwait, Mandeep K., Zofia Piotrowska, Karen Yun, et al.. (2025). Clinical factors and molecular co-alterations impact outcomes in patients receiving first-line osimertinib for EGFR-mutated non-small cell lung cancer. Lung Cancer. 208. 108747–108747.
2.
Riess, Jonathan W., Adrianus J. de Langen, Santiago Ponce, et al.. (2025). ORCHARD: Osimertinib Plus Necitumumab in Patients With Epidermal Growth Factor Receptor–Mutated Advanced Non–Small Cell Lung Cancer With a Secondary Epidermal Growth Factor Receptor Alteration Whose Disease Had Progressed on First-Line Osimertinib. JCO Precision Oncology. 9(9). e2400818–e2400818.
3.
Mak, Raymond H., Michael Lanuti, Alona Muzikansky, et al.. (2024). The ASCENT Trial: a phase 2 study of induction and consolidation afatinib and chemoradiation with or without surgery in stage III EGFR-mutant NSCLC. The Oncologist. 29(7). 609–618.
4.
Meador, Catherine B., Subba R. Digumarthy, Beow Y. Yeap, et al.. (2024). Phase I/II Investigator-Initiated Study of Olaparib and Temozolomide in SCLC: Final Analysis and CNS Outcomes. Clinical Cancer Research. 31(1). 25–34.
5.
Keane, Florence K., Beow Y. Yeap, Melin J. Khandekar, et al.. (2024). Phase 2 Trial of Consolidative Stereotactic Body Radiation Therapy in Patients With Metastatic Oncogene-driven Non-small Cell Lung Carcinoma Treated With Tyrosine Kinase Inhibitors. International Journal of Radiation Oncology*Biology*Physics. 121(4). 975–979.
6.
Passaro, Angelina, Victor Lee, Sung‐Han Kim, et al.. (2024). 1254MO Safety and anti-tumour activity of zipalertinib in NSCLC patients (pts) with EGFR exon 20 insertion (ex20ins) mutations who received prior amivantamab. Annals of Oncology. 35. S803–S804.
7.
Dagogo‐Jack, Ibiayi, Alissa J. Cooper, Justin F. Gainor, et al.. (2024). Alectinib combined with cobimetinib in ALK-Rearranged lung Cancer: A phase IB study. Lung Cancer. 199. 108003–108003.
8.
Tzeng, Alice, Kelly Fitzgerald, Jaclyn LoPiccolo, et al.. (2023). Pneumonitis in Patients Receiving Thoracic Radiotherapy and Osimertinib: A Multi-Institutional Study. JTO Clinical and Research Reports. 4(10). 100559–100559.
9.
Lee, Jiyun, Zofia Piotrowska, Ross A. Soo, Byoung Chul Cho, & Sun Min Lim. (2022). Combatting acquired resistance to osimertinib in EGFR-mutant lung cancer. Therapeutic Advances in Medical Oncology. 14. 4287556131–4287556131.
10.
Piper‐Vallillo, Andrew J., Rebecca M. Gardner, Kristen Cunanan, et al.. (2021). Chemotherapy Plus Immunotherapy Versus Chemotherapy Plus Bevacizumab Versus Chemotherapy Alone in EGFR-Mutant NSCLC After Progression on Osimertinib. Clinical Lung Cancer. 23(3). e210–e221.
11.
Cornelissen, Robin, Sanyuan Sun, Marina Chiara Garassino, et al.. (2021). LBA46 Efficacy and safety of poziotinib in treatment-naïve NSCLC harboring HER2 exon 20 mutations: A multinational phase II study (ZENITH20-4). Annals of Oncology. 32. S1324–S1324.
12.
McClatchy, David M., Henning Willers, Aaron N. Hata, et al.. (2020). Modeling Resistance and Recurrence Patterns of Combined Targeted–Chemoradiotherapy Predicts Benefit of Shorter Induction Period. Cancer Research. 80(22). 5121–5133.
13.
Bertino, Erin M., Ryan D. Gentzler, Jill Kolesar, et al.. (2020). Phase IB Study of Osimertinib in Combination with Navitoclax in EGFR-mutant NSCLC Following Resistance to Initial EGFR Therapy (ETCTN 9903). Clinical Cancer Research. 27(6). 1604–1611.
14.
Grassberger, Clemens, David M. McClatchy, Changran Geng, et al.. (2019). Patient-Specific Tumor Growth Trajectories Determine Persistent and Resistant Cancer Cell Populations during Treatment with Targeted Therapies. Cancer Research. 79(14). 3776–3788.
15.
Leaf, Rebecca Karp, Deepa Rangachari, James W. Mier, et al.. (2019). Clinical and laboratory features of autoimmune hemolytic anemia associated with immune checkpoint inhibitors. American Journal of Hematology. 94(5). 563–574.
16.
Jorge, Susan E., Antonio R. Lucena‐Araujo, Hiroyuki Yasuda, et al.. (2018). EGFR Exon 20 Insertion Mutations Display Sensitivity to Hsp90 Inhibition in Preclinical Models and Lung Adenocarcinomas. Clinical Cancer Research. 24(24). 6548–6555.
17.
Khandekar, Melin J., Zofia Piotrowska, Henning Willers, & Lecia V. Sequist. (2018). Role of Epidermal Growth Factor Receptor (EGFR) Inhibitors and Radiation in the Management of Brain Metastases from EGFR Mutant Lung Cancers. The Oncologist. 23(9). 1054–1062.
18.
Gadgeel, Shirish M., Wei Chen, Zofia Piotrowska, et al.. (2017). P3.02b-115 Clinical Activity of Osimertinib in EGFR Mutation Positive Non-Small Cell Lung Cancer (NSCLC) Patients (Pts) Previously Treated with Rociletinib. Journal of Thoracic Oncology. 12(1). S1263–S1263.
19.
Niederst, Matthew J., Haichuan Hu, Hillary E. Mulvey, et al.. (2015). The Allelic Context of the C797S Mutation Acquired upon Treatment with Third-Generation EGFR Inhibitors Impacts Sensitivity to Subsequent Treatment Strategies. Clinical Cancer Research. 21(17). 3924–3933.
20.
Piotrowska, Zofia, Matthew J. Niederst, Mari Mino–Kenudson, et al.. (2014). Variation in Mechanisms of Acquired Resistance Among EGFR-Mutant NSCLC Patients With More Than 1 Postresistant Biopsy. International Journal of Radiation Oncology*Biology*Physics. 90(5). S6–S7.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Teresa Morán Breakdown of academic impact, for papers by Alessandro Leonetti Breakdown of academic impact, for papers by Francesco Facchinetti Breakdown of academic impact, for papers by Jennifer Tursi Breakdown of academic impact, for papers by Maximilian J. Hochmair Breakdown of academic impact, for papers by C. Anger Breakdown of academic impact, for papers by Hai‐Yan Tu Breakdown of academic impact, for papers by Miloš Pešek Breakdown of academic impact, for papers by Richard Eek Breakdown of academic impact, for papers by Katsuhiro Masago